Delivery Order SPE2DB24D9144-SPE2DB25FCMZY
- Not listed
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a $8,622.72 firm fixed-price delivery order by the Defense Logistics Agency (DLA) on September 3, 2025, for the supply of Xtandi 40 mg capsules (120-count units). The contract, which carries no set-aside designation, is set for ultimate completion by September 4, 2025, and represents a delivery order issued under DMS Pharmaceutical Group's substantial Indefinite...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order by the Defense Logistics Agency (DLA) on August 5, 2025, for the supply of Xtandi 40 mg tablets (120-count packages). The contract, valued at $8,339.18 with an ultimate completion date of August 6, 2025, carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's existing single-award Indefinite...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $25,868.10 by the Defense Logistics Agency for the supply of Xtandi 40 mg capsules (120-count units). The contract is firm fixed-price with an ultimate completion date of September 2, 2025, and carries no set-aside designation. This delivery order represents one of numerous pharmaceutical supply contracts issued to DMS Pharmaceutical Group...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order by the Defense Logistics Agency (DLA) on September 9, 2025, for the supply of Xtandi 40 mg tablets (120-count units) with a ceiling value of $8,339.18. This firm fixed-price delivery order, which is scheduled for completion by September 10, 2025, represents a tactical execution under DMS Pharmaceutical Group's larger Indefinite Delivery Contract...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order by the Defense Logistics Agency (DLA) on September 11, 2025, for the supply of Xtandi 40 mg tablets (120-count units). The contract, valued at $8,339.18 with a completion date of September 12, 2025, carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, received a delivery order award from the Defense Logistics Agency (DLA) on August 8, 2025, for the supply of Xtandi 40 mg capsules (120-count units). This firm fixed-price delivery order, valued at $8,622.72 with an ultimate completion date of August 11, 2025, carries no set-aside designation. The award falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $4,311.35 by the Defense Logistics Agency (DLA) on July 31, 2025, for the supply of Xtandi 40 mg capsules (120-count units). The delivery order carries an ultimate completion date of August 1, 2025, and was issued without set-aside designation. This award represents a single delivery order issued under DMS Pharmaceutical...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order by the Defense Logistics Agency on September 4, 2025, for the supply of Xtandi 40 mg capsules (120-count units) with a ceiling value of $17,245.40. The contract is structured as a firm fixed-price delivery order with an ultimate completion date of September 5, 2025. This award carries no set-aside designation, demonstrating the company's competitive...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $8,339.18 by the Defense Logistics Agency (DLA) on August 11, 2025, for the supply of Xtandi 80 mg tablets (60-count units). The contract utilizes a firm fixed-price structure with no set-aside designation and is scheduled for completion by August 12, 2025. This delivery order falls under DMS Pharmaceutical Group's larger Indefinite...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, received a delivery order award from the Defense Logistics Agency (DLA) on July 21, 2025, for the supply of Xtandi 40 mg capsules (120-count units). This firm fixed-price delivery order, valued at $4,311.35, is set to be completed by July 22, 2025, and will be performed at the vendor's Park Ridge, Illinois location. The award carries no set-aside designation, allowing DMS...
- SPE2DB24D9144Indefinite Delivery Contract
- SPE2DB24D9144-SPE2DB25FCMZYDelivery Order
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order by the Defense Logistics Agency (DLA) on September 10, 2025, for the supply of Xtandi 40 mg capsules (120-count units). The contract ceiling value is $38,376.87, with an ultimate completion date of September 11, 2025. This delivery order carries no set-aside designation and represents a direct fulfillment order under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with the DLA under the SPE2DB program, a $500 million vehicle valid through November 2026 that enables the agency to procure a comprehensive range of pharmaceutical products for military healthcare facilities. Xtandi is a prescription oncology medication used in the treatment of prostate cancer, reflecting DMS Pharmaceutical Group's established role as a critical supplier of specialty pharmaceuticals to Department of Defense healthcare systems. The company's positioning as a federal pharmaceutical distributor has been built through consistent contract awards with the DLA for branded and generic prescription drugs, biologics, and medical consumables serving military medical facilities nationwide. This delivery order exemplifies the operational efficiency of the SPE2DB program in enabling rapid procurement of needed pharmaceutical supplies to support military health services.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $38.4k | 9/10/25 |